The anxiolytic effects of a Valerian extract is based on Valerenic acid

BMC Complementary and Alternative Medicine

Volumn 14, Issue , 2014, Pages

  Becker, Axel ^a   Felgentreff, Falko ^a   Schröder, Helmut ^a   Meier, Beat ^b   Brattström, Axel ^c  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b ZURICH UNIVERSITY OF APPLIED SCIENCES   (Switzerland)

^c Alexander Puschkin Str 50 ^*  (Germany)

Author keywords

Anxiety; Binding; Elevated plus maze; Valerenic acid; Valerian extract

Indexed keywords

4 AMINOBUTYRIC ACID; ACETOXY VALERENIC ACID; CHLORDIAZEPOXIDE; DIAZEPAM; FLUNITRAZEPAM; PLANT MEDICINAL PRODUCT; UNCLASSIFIED DRUG; VALERENIC ACID; VALERIAN; 4 AMINOBUTYRIC ACID A RECEPTOR; ANXIOLYTIC AGENT; BENZODIAZEPINE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANXIETY; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BODY TEMPERATURE; CONTROLLED STUDY; CORE TEMPERATURE; DRUG BINDING; DRUG BINDING SITE; ELEVATED PLUS MAZE TEST; FRONTAL CORTEX; MALE; MOUSE; NONHUMAN; RAT; TRANQUILIZING ACTIVITY; ANIMAL BEHAVIOR; ANIMAL MODEL; ELECTRONIC THERMOMETER; RHIZOME;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; FRONTAL LOBE; INDENES; MALE; MAZE LEARNING; MICE; PLANT EXTRACTS; RATS; RECEPTORS, GABA-A; SESQUITERPENES; VALERIAN;

EID: 84904772554     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/1472-6882-14-267     Document Type: Article

References (21)

1. Benke D, Barberis A, Kopp S, Altmann KH, Schubiger M, Vogt KE, Rudolph U, Möhler H. GABAA receptors as in vivo substrate for the anxiolytic action of valerenic acid, a major constituent of valerian root extracts. Neuropharmacology 2009, 56(1):174-181.
2. Khom S, Strommeier B, Ramharter J, Schwarz T, Schwarzer C, Erker T, Ecker GF, Mulzer J, Hering S. Valerenic acid derivatives as novel subunit-selective ligands - in vitro and in vivo characterization. Br J Pharmacol 2010, 161(1):65-78. 10.1111/j.1476-5381.2010.00865.x, 2962817, 20718740.
3. Murphy K, Kubin ZJ, Shepherd JN, Ettinger RH. Valeriana officinalis root extracts have potent anxiolytic effects in laboratory rats. Phytomedicine 2010, 17:674-678. 10.1016/j.phymed.2009.10.020, 20042323.
4. Khom S, Baburin I, Timin E, Hohaus A, Trauner G, Kopp B, Hering S. Valerenic acid potentiates and inhibits GABAA receptors: molecular mechanism and subunit specificity. Neuropharmacology 2007, 53(1):178-187. 10.1016/j.neuropharm.2007.04.018, 17585957.
5. Trauner G, Khom S, Baburin I, Benedek B, Hering S, Kopp B. Modulation of GABAA receptors by valerian extracts is related to the content of valerenic acid. Planta Med 2007, 74:19-24.
6. Felgentreff F, Becker A, Meier B, Brattström A. Valerian extract characterized by high valerenic acid and low azetoxy valerenic acid contents demonstrates anxiolytic activity. Phytomedicine 2012, 19:1216-1222. 10.1016/j.phymed.2012.08.003, 22944521.
7. Navarrete A, Avula B, Choi YW. Chemical fingerprinting of valerian species: simultaneous determination of valerenic acids, flavonoids, and phenylpropanoids using liquid chromatography with ultraviolet detection. J AOAC Int 2006, 89:8-18.
8. Yakimova KS, Sann H, Schmid HA, Pierau FK. Effects of GABA agonists and antagonists on temperature-sensitive neurons in the rat hypothalamus. J Physiol 1996, 494:217-230. 1160625, 8814617.
9. Zarrindast MR, Dibayan M. Involvement of GABAA receptor sites in diazepam induced hypothermia. Gen Pharmacol 1998, 20:855-859.
10. Nikolov RP, Yakimova KS. Effects of GABA-transaminase inhibitor Vigabatrin on thermoregulation in rats. Amino Acids 2011, 40(5):1441-1445. 10.1007/s00726-010-0754-5, 20878340.
11. Rodgers RJ. Animal models of anxiety: where next?. Behav Pharmacol 1997, 8:477-496. 10.1097/00008877-199711000-00003, 9832964.
12. Goppel M, Franz G. Stability control of valerian ground material and extracts: a new HPLC-method for the routine quantification of valerenic acids and lignans. Pharmazie 2003, 59:446-452.
13. Fernández S, Wasowski C, Paladini AC, Marder M. Sedative and sleep-enhancing properties of linarin, a flavonoid-isolated from Valeriana officinalis. Pharmacol Biochem Behav 2004, 77(2):399-404. 10.1016/j.pbb.2003.12.003, 14751470.
14. Marder M, Viola H, Wasowski C, Fernández S, Medina JH, Paladini AC. 6-methylapigenin and hesperidin: new valeriana flavonoids with activity on the CNS. Pharmacol Biochem Behav 2003, 75(3):537-545. 10.1016/S0091-3057(03)00121-7, 12895671.
15. Yuan CS, Mehendale S, Xiao Y, Aung HH, Xie JT, Ang-Lee MK. The gamma-aminobutyric acidergic effects of valerian and valerenic acid on rat brainstem neuronal activity. Anaesth Analg 2004, 98(2):353-358.
16. Sampath C, Haug K, Thanel S, Hamburger M, Derendorf H, Frye R, Butterweck V. Pharmacokinetics of valerenic acid in rats after intravenous and oral administrations. Planta Med 2012, 78:575-581. 10.1055/s-0031-1298301, 22411722.
17. Awad R, Levac P, Cybulska P, Merali Z, Trudeau VL, Arnason JT. Effects of traditionally used anxiolytic botanicals on enzymes of the γ-aminobutyric acid (GABA). Can J Physiol Pharmacol 2007, 85:933-942. 10.1139/Y07-083, 18066140.
18. Del Valle-Mojica LM, Ayala-Marin YM, Ortiz-Sanchez CM, Torres-Hernandez BA, Abdalla-Mukhaimer S, Ortiz JG. Selective interactions of Valeriana officinalis extracts and valerenic acid with [3H] glutamate binding to rat synaptic membranes. Evid Based Complementary Altern Med 2011, doi:10.1155/2011/403591.
19. de Gage Billoti S, Begaud B, Bazin F, Verdoux H, Dartigues JF, Peres K, Kurth T, Pariente A. Benzodiazepine use and risk of dementia: prospective population based study. BMJ 2012, doi:10.1136/bmj.e6231.
20. Olsen RW, Sieghart W. Internationale Union of Pharmacology. LXX. Subtypes of γ-aminobutyric acid A receptors: classification on the basis of subunit composition, pharmacology, and function. Update. Pharmacol Rev 2008, 60(3):242-260.
21. Ramerstorfer J, Furtmüller R, Sarto-Jackson I, Varagic Z, Sieghart W. The GABAA receptor α+β-interface: a novel target for subtype selective drugs. J Neurosci 2011, 31:870-877. 10.1523/JNEUROSCI.5012-10.2011, 3182524, 21248110.